Literature DB >> 8875246

Myotonic dystrophy: will the real gene please step forward!

S Harris1, C Moncrieff, K Johnson.   

Abstract

The mutation underlying myotonic dystrophy (DM) was identified at the end of 1991 amidst great rejoicing from the patients supporting the research and, not least, from those who spent so long searching for it. Subsequently, the molecular genetic phenomena associated with DM have been clearly explained by the transmission behaviour of the expanding repeat, which remains the only mutation that has been described in patients. We understand the molecular basis of anticipation, why the severe congenital form is almost exclusively transmitted by affected mothers and we have widely accepted models of the population genetics of DM. Yet, despite all these clearly explained molecular events, we appear to be hardly any closer to understanding the molecular pathology of DM than when the mutation was first identified. To understand the reason for this, we have to look in detail at the mutation itself, and in particular at the locus and its complex nuances. In doing so, we begin to realise that DM is unique amongst the Mendelianly inherited disorders, in that the mutation, because of its location in a very gene-rich region of the genome, probably simultaneously renders several genes dysfunctional. The somatic heterogeneity of the repeat, coupled with the involvement of several genes, accounts for the pleiotropy observed in the phenotype. Added to this complexity is the uncertainty of the level at which gene dysfunction or gain of function is occurring. It is possibly at the level of DNA/chromatin structure and/or RNA regulation/processing, and all of these pathways may, in different tissues, contribute to the final phenotype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875246     DOI: 10.1093/hmg/5.supplement_1.1417

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  7 in total

1.  Transcriptional abnormality in myotonic dystrophy affects DMPK but not neighboring genes.

Authors:  M G Hamshere; E E Newman; M Alwazzan; B S Athwal; J D Brook
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues.

Authors:  Arturo López Castel; Masayuki Nakamori; Stephanie Tomé; David Chitayat; Geneviève Gourdon; Charles A Thornton; Christopher E Pearson
Journal:  Hum Mol Genet       Date:  2010-11-01       Impact factor: 6.150

Review 3.  RNA surveillance: molecular approaches in transcript quality control and their implications in clinical diseases.

Authors:  Karen C M Moraes
Journal:  Mol Med       Date:  2009-10-07       Impact factor: 6.354

Review 4.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

5.  Long CAG/CTG repeats in mice.

Authors:  B L King; G Sirugo; J H Nadeau; T J Hudson; K K Kidd; B M Kacinski; M Schalling
Journal:  Mamm Genome       Date:  1998-05       Impact factor: 2.957

6.  Polymorphisms of the glucocorticoid receptor gene in laboratory and wild rats: steroid binding properties of trinucleotide CAG repeat length variants.

Authors:  R P Heeley; E Gill; B van Zutphen; C J Kenyon; R G Sutcliffe
Journal:  Mamm Genome       Date:  1998-03       Impact factor: 2.957

7.  Myotonic dystrophy type 1 (DM1) clinical subtypes and CTCF site methylation status flanking the CTG expansion are mutant allele length-dependent.

Authors:  Fernando Morales; Eyleen Corrales; Baili Zhang; Melissa Vásquez; Carolina Santamaría-Ulloa; Hazel Quesada; Mario Sirito; Marcos R Estecio; Darren G Monckton; Ralf Krahe
Journal:  Hum Mol Genet       Date:  2021-12-27       Impact factor: 5.121

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.